Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892385 · ClinicalTrials.gov registry record · Phase 1
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00892385 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 66 participants.
The verdict
NCT00892385, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as methoxyamine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of methoxyamine when given together with temozolomide in treating patients with advanced solid tumors.
Interventions
- DRUG Temozolomide
- DRUG Methoxyamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2007-08-16 |
| Est. Completion | 2017-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892385
The ClinicalTrials.gov registry entry for NCT00892385 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00892385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00892385 about?
NCT00892385 is a clinical study titled "Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as methoxyamine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with temozolomide may kill more tumor cells. PURPOSE: This phase I tria...
What is the current status of trial NCT00892385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2007-08-16. Estimated completion is 2017-03-08.
What interventions are being tested in trial NCT00892385?
The interventions under investigation include: Temozolomide (DRUG), Methoxyamine (DRUG).
Who is sponsoring clinical trial NCT00892385?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.